SOURCE: Hansen Medical, Inc.

Hansen Medical, Inc.

January 29, 2015 09:00 ET

Hansen Medical to Showcase Magellan™ Robotic System at 2015 International Aortic Summit (IAS)

MOUNTAIN VIEW, CA--(Marketwired - Jan 29, 2015) - Hansen Medical, Inc. (NASDAQ: HNSN), a global leader in intravascular robotics, today announced it will exhibit its Magellan™ Robotic System at the International Aortic Summit (IAS) from February 11-13 at the Hyatt Regency in Palm Beach, AW. The Company will showcase its Magellan Robotic Catheters and will conduct Magellan Robotic System demonstrations at exhibit booth #11.

"As I have experienced in my own practice, the Magellan Robotic System is a significant advancement in the treatment of vascular disease," said IAS course Co-Director Dr. Joseph J. Ricotta, MD. "We are pleased to offer hands-on learning opportunities with Magellan at IAS 2015, and we look forward to discussing the potential for intravascular robotics to contribute to procedural predictability and reduce operator radiation exposure when treating complex aortic disease via a least invasive, endovascular approach."

Northside Hospital, where Dr. Ricotta is Chair, Department of Vascular Surgery and Endovascular Therapy and Medical Director of the Heart and Vascular Institute, recently became the first in Georgia to offer Magellan robotic procedures, with implementation of Magellan systems at both its Atlanta and Forsyth locations. Dr. Ricotta performed approximately 15 Magellan procedures shortly after completing training, with an initial focus on treatment of lower extremity peripheral artery disease, and now expanding into aortic, venous and other vascular procedures.

The IAS is an assembly of leaders in the fields of vascular and endovascular surgery to present and discuss the latest advances in aortic surgery (both open and endovascular techniques). According to Millennium Research Group(1), approximately 140,000 procedures are performed annually in the U.S. & Europe for repair of aortic and thoracic aneurysms. Minimally-invasive endovascular repairs account for approximately two-thirds of these procedures, and are forecasted to grow 6.5% annually through 2020.

"We are excited to participate in this year's International Aortic Summit," said Cary Vance, Hansen Medical's President and Chief Executive Officer. "The Magellan Robotic System is playing an important role in helping to enable endovascular treatment of complex aortic disease. We look forward to working alongside the other innovative companies and physicians at IAS who are focused on advancing treatment options for this large group of patients."

About the Magellan™ Robotic System
Hansen Medical's Magellan Robotic System is intended to be used to facilitate navigation in the peripheral vasculature and subsequently provide a conduit for manual placement of therapeutic devices. The Magellan Robotic System is designed to deliver predictability, control and catheter stability to endovascular procedures. Since its commercial introduction in the U.S. and Europe, the Magellan Robotic System has demonstrated its clinical versatility in many cases in a broad variety of peripheral vascular procedure types in centers across the U.S. and Europe. The Magellan Robotic System offers several important features including:

  • Provides predictability, control and catheter stability as a physician navigates a patient's peripheral vasculature and then provides a conduit for manual treatment of vascular disease with standard therapeutic devices.
  • Is designed to enable more predictable procedure times and increased case throughput potentially allowing hospitals to improve utilization within their vascular business line.
  • Employs an open architecture designed to allow for the subsequent use of many therapeutic devices on the market today.
  • Is designed to potentially reduce physician radiation exposure and fatigue by allowing the physician to navigate procedures while seated comfortably at a remote workstation away from the radiation field and without wearing heavy lead as required in conventional endovascular procedures. 
  • The Magellan 9Fr Robotic Catheter allows for independent, robotic control of the distal tip of two telescoping catheters (an outer Guide and an inner Leader catheter), as well as robotic manipulation of standard guide wires.
  • The Magellan 6Fr Robotic Catheter allows for independent robotic control of two separate bend sites on a single catheter, as well as robotic manipulation of standard guide wires. This smaller catheter design may be preferred by certain physicians who prefer a smaller diameter vessel access site, or in procedures in smaller vessels. 

About Hansen Medical, Inc.
Hansen Medical, Inc., based in Mountain View, California, is a global leader in Intravascular Robotics, developing products and technology designed to enable the accurate positioning, manipulation and control of catheters and catheter-based technologies. The Company's Magellan™ Robotic System, 9Fr Magellan™ Robotic Catheter, Magellan™ 6Fr Robotic Catheter, and related accessories are intended to facilitate navigation to anatomical targets in the peripheral vasculature and subsequently provide a conduit for manual placement of therapeutic devices. The Company's mission is to enable Cardiac Arrhythmia and Endovascular Procedures and to improve patient outcomes through the use of Intravascular Robotics. Additional information can be found at www.hansenmedical.com.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including statements containing the words "plan," "expects," "potential," "believes," "goal," "estimate," "anticipates," and other similar words. These statements are based on the current estimates and assumptions of our management as of the date of this press release and are subject to risks, uncertainties, changes in circumstances and other factors that may cause actual results to differ materially from the information expressed or implied by forward-looking statements made in this press release. Examples of such statements include statements regarding the potential benefits of our robotic systems for hospitals, patients and physicians. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, among others: factors relating to engineering, regulatory, manufacturing, sales and customer service challenges in developing new products and entering new markets; potential safety and regulatory issues that could slow or suspend our sales; the effect of credit, financial and economic conditions on capital spending by our potential customers; the rate of adoption of our systems and the rate of use of our catheters; our ability to manage expenses and cash flow, and obtain adequate financing; and other risks more fully described in the "Risk Factors" in our annual report on Form 10-K for the year ended December 31, 2013, as updated from time to time by our quarterly reports on Form 10-Q and our other filings with the Securities and Exchange Commission. Given these uncertainties, you should not place undue reliance on the forward-looking statements in this press release. We undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available.

"Artisan Extend," "Hansen Medical," "Hansen Medical (with Heart Design)," "Heart Design (Logo)," "Sensei," "Lynx," "Artisan," "Instinctive Motion," "Fine Force Technology," "IntelliSense" are registered trademarks, and "Magellan" and "Hansen Medical Magellan" are trademarks of Hansen Medical, Inc. in the U.S. and other countries.

(1) US Markets for Peripheral Vascular Devices 2014, European Markets for Peripheral Vascular Devices 2014, Millennium Research Group Report